Segmental distribution of vascular resistances during ureteral occlusion. The vasoconstrictive effects of angiotensin and CaCl2 differ from those of catecholamines and renal nerve stimulation.
Examinations of renal autoregulation and renin release suggest that alpha-adrenergic agonists, in contrast to other vasoconstrictors, preferentially constrict the preglomerular arteries. To examine this hypothesis, experiments were performed in anesthetized dogs during ureteral occlusion. At a ureteral pressure (UP) of 100 mmHg the afferent arterioles are dilated and mechanical constriction of the renal artery does not alter intrarenal vascular resistances. Whereas angiotensin and CaCl2 infused into the renal artery reduced renal blood flow (RBF) by 25-30% without reducing UP, renal nerve stimulation reduced RBF and UP in proportion. During angiotensin and catecholamine infusion, measurements of UP and intrarenal venous pressure permitted calculations of preglomerular, efferent vascular and intrarenal venous resistances. Until RBF was reduced by 25%, angiotensin raised both preglomerular and efferent vascular resistances, whereas norepinephrine and the alpha-adrenergic agonists, phenylephrine and methoxamine, raised preglomerular more than efferent vascular resistance. When RBF was reduced by more than 25%, all vasoconstrictors showed a similar pattern with large increments both in preglomerular and efferent vascular resistances.


CONCLUSIONS
Humoral and nervous stimulation of alpha-adrenergic receptors reduce glomerular capillary pressure by preferentially constricting the preglomerular arteries and may affect renal autoregulation and renin release by reducing the transmural pressure of the afferent arterioles.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000804:Angiotensin II / Q000494:pharmacology*; D000818:Animals; D002122:Calcium Chloride / Q000494:pharmacology*; D002199:Capillary Permeability / Q000187:drug effects; D004285:Dogs; D005260:Female; D006706:Homeostasis / Q000187:drug effects; D007668:Kidney / Q000098:blood supply* / Q000294:innervation; D008297:Male; D008729:Methoxamine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology*; D010656:Phenylephrine / Q000494:pharmacology*; D011312:Pressure; D014513:Ureter / Q000502:physiology*; D014655:Vascular Resistance / Q000187:drug effects*; D014661:Vasoconstriction / Q000187:drug effects*; D014690:Venous Pressure / Q000187:drug effects
D000316:Adrenergic alpha-Agonists; D000804:Angiotensin II; D010656:Phenylephrine; D008729:Methoxamine; D002122:Calcium Chloride; D009638:Norepinephrine